One of the major obstacles hindering the treatment of lung cancer (LC) is chemoresistance; however, its mechanism remains unclear. The overexpression of the metastasis-associated in colon cancer 1 (MACC1) gene has been demonstrated to reverse chemoresistance. In the current study, the expression of MACC1 in LC cells with cisplatin resistance (Cis-Re) was investigated. Cisplatinresistant cell sublines (A549/CR and H446/CR) were induced by stepwise escalation of cisplatin exposure. MTS and flow cytometry assays were performed to measure cell proliferation and apoptosis, respectively. Western blot analysis and qRT-PCR assays were performed to determine the changes in signaling pathway-related protein and mRNA levels, respectively. A nude mouse xenograft model was used for in vivo experiments. Our results showed that MACC1 expression was increased in the cisplatin-resistant A549/CR and H446/CR cell lines, and the resistance was reversed with a decrease of MACC1 expression. MACC1 overexpression triggered an increase of Cis-Re, which was contrary to the effect of MACC1 down-regulation. In addition, the effect of MACC1 on Cis-Re was blocked by the inhibition of the PI3K/AKT pathway, and treatment with both cisplatin and a PI3K/AKT inhibitor effectively inhibited tumor growth in xenografts with MACC1 overexpression. In conclusion, our results revealed that MACC1 increased Cis-Re partially via the PI3K/AKT signaling pathway, suggesting that MACC1 could serve as a potential target to overcome Cis-Re. Furthermore, combination therapy could alleviate Cis-Re resulted from MACC1 overexpression in patients with LC.
Introduction
Lung cancer (LC) has become a major course to death caused by cancers [1] . Non-small cell LC (NSCLC) and small cell LC (SCLC) are the main types of LC, and the mortality rate (25%) of LC in the USA is higher than the combined mortality rates of the most deadly types of tumors [2] . LC is also a leading cause of cancer-related death globally [3] . In some developing countries, the incidence of LC is increasing due to tobacco abuse [4, 5] . The widespread use of cisplatin-based chemotherapy has increased the cure rate of patients by 5%-10%, which corresponds to a notable improvement in postoperative progression-free survival (PFS) [6, 7] . Simultaneous radiochemotherapy is superior to single radiotherapy in terms of the median survival and PFS [8] .
A disruption in the regulation of HER2 downstream signaling pathways, such as the PI3K/AKT pathway, is considered as one of the mechanisms of cisplatin resistance (Cis-Re) [9] . Previously studies reported that the metastasis-associated in colon cancer 1 (MACC1) gene is upregulated in a variety of cancers, and it can be used as an indicator of tumor infiltration and metastasis [10] [11] [12] . Moreover, the upregulation of the MACC1 gene is induced by metabolic stress in LC through the AMP-activated protein kinase signaling pathway, which could further amplify the Warburg effect and accelerate disease progression by increasing the resistance of patients to metabolic stress [13, 14] . MACC1 has been identified as a regulator in some pathways, and some studies have focused on the role of MACC1 in LC [15, 16] .
Here, we investigated the expression of MACC1 in LC cells with Cis-Re. The significant upregulation of MACC1 was first identified in cisplatin-resistant A549/CR and H446/CR cells, and MACC1 was found to induce the development of Cis-Re through the PI3K/ AKT pathway. To further elucidate the role of MACC1 in the development of Cis-Re, we analyzed the correlation between MACC1 expression and the development of Cis-Re in LC.
Materials and Methods
Cell culture and chemicals A549 and H446 human LC cells (ATCC, Manassas, USA) were cultured in RPMI 1640 medium containing 10% fetal bovine serum in a humidified incubator (37°C with 5% CO 2 ). Cisplatin-resistant A549/CR and H446/CR cells were generated by treating parental A549 and H446 cells with 1 μg/ml cisplatin for 6 months and 4 μg/ ml cisplatin for an additional 3 months. The anticancer chemicals, cisplatin (Roche, Pleasanton, USA) and perifosine (Selleckchem, Houston, USA), were diluted with DMSO.
MTS assay
MTS assay was performed using a Cell Proliferation Assay kit (Promega, Madison, USA) [17, 18] . In brief, cells were seeded into a 96-well plate and cultured overnight. After 72 h of incubation, cell viability was determined using the MTS assay kit following the manufacturer's instructions. Wallac Victor 1420 Multilabel Counter (Perkin Elmer, Waltham, USA) was used to measure the absorbance at 490 nm. Each experiment was conducted in triplicate.
Western blot analysis
After cell lysis, total protein concentration was determined using a BCA assay kit (Thermo Scientific, Waltham, USA) and analyzed by SDS-PAGE. The bands were transferred onto a nitrocellulose membrane which was later blocked with skimmed milk (5%) and incubated with primary antibodies overnight. Then, the membrane was incubated with horseradish peroxidase-conjugated secondary antibodies for 2 h. An enhanced chemiluminescence kit was used to visualize the protein bands. The primary antibody against MACC1 was from Sigma (St Louis, USA), and antibodies against β-actin, AKT, and p-AKT were from Cell Signaling Technology (Danvers, USA). 
qRT-PCR analysis

Apoptosis assay
After overnight culture in a 6-well plate, cells were treated with cisplatin and harvested after 24 h. The apoptosis of these cells and control cells that were not treated with cisplatin was detected using an apoptosis kit (BD, Franklin Lakes, USA). In brief, the cells were rinsed with pre-cooled PBS two times and incubated in binding buffer for 15 min in a dark room. Then, cell apoptosis was detected by flow cytometry (FACS; BD). Caspase activity was determined using a Cell Death Detection ELISA kit (Roche) according to the manufacturer's protocol.
Transient cell transfection
Lipofectamine 2000 (Invitrogen) was used to transfect cells with plasmids following the manufacturer's instructions. The cells were then inoculated into a 6-well plate at a density of 3 × 10 5 cells/well, incubated for 24 h, and treated with the corresponding drug.
Knockdown experiments were performed 24 h prior to drug treatment using 300 pmol of siRNA. The control scrambled siRNA (5′-UAAGGCUAUGAAGAGAUAC-3′) and siRNA for MACC1 (sc-89466; 5′-AAGAUUGGACUUGUACACUGCTT-3′) were obtained from Santa Cruz Biotechnology (Santa Cruz, USA).
Xenograft mouse model
All animal experiments were performed in accordance with Institutional Ethical Guidelines for Animal Experiment. The study was approved by the Committee on the Ethics of Animal Experiments of Tianjin Medical University Cancer Institute and Hospital. Female nude mice (aged 5-6 weeks) were purchased from SLAC Laboratory Animal Co., Ltd (Shanghai, China). After the pre-treatment of A549 cells with different plasmids or the negative control (NC), a cell suspension was prepared with 100 μl PBS at a density of 4 × 10 6 cells/ml for peritoneal injection into the nude mice (n = 6). To evaluate tumor growth, the volume of the tumor was calculated by measuring the necessary parameters using a caliper, which were then substituted into the formula: volume = 1/2 × length × width 2 . Once the tumor volume reached 1.0 cm 3 , the mice were euthanized for tumor resection.
Statistical analysis
Data are presented as the mean ± standard deviation (SD). The data were analyzed by one-way ANOVA or t-test using GraphPad Prism V software. P < 0.05 indicated that the difference was statistically significant.
Results
Construction of cancer cells with Cis-Re
To investigate the mechanism of Cis-Re in LC, A549/CR and H446/ CR cells were established by culturing A549 and H446 cells with 1 μg/ml cisplatin for 6 months and then with 4 μg/ml cisplatin for an additional 3 months. No obvious changes in cellular morphology were observed in A549/CR and H446/CR cells. In comparison with parental cells, A549/CR and H446/CR cells grew more slowly (Fig. 1A) . As expected, cisplatin treatment significantly suppressed The indicated cell lines were treated with increasing concentrations of CPT-11 for 72 h. Cell proliferation was determined by MTS assay. These data are expressed as the mean ± SD of three independent experiments. *P < 0.05; **P < 0.01. the growth and induced the apoptosis of parental cells but did not affect cisplatin-resistant cells (Fig. 1B,C) . A549/CR and H446/CR cells showed no resistance to CPT-11 (Fig. 1D) . Hence, cells with Cis-Re were successfully prepared.
MACC1 induction of Cis-Re in cancer cells
The effect of MACC1 expression on the resistance of LC cells to cisplatin was investigated. Contrary to the expected results, the expression of MACC1 was significantly higher in cisplatin-resistant cells than that in parental cells ( Fig. 2A,B) . Subsequently, in order to elucidate the regulatory role of MACC1 in the development of Cis-Re in LC cells, the expression of MACC1 in A549/CR and H446/CR cells was downregulated using siRNA (Fig. 2C) . The viability of MACC1 downregulated cells was markedly decreased compared with that of the cisplatin-resistant cells. Therefore, targeting MACC1 reversed the Cis-Re observed in LC cells (Fig. 2D) . These results suggested that MACC1 could mediate Cis-Re in LC cells. (Fig. 3A,  B) . In addition, upregulated exogenous MACC1 expression suppressed cisplatin-induced apoptosis (Fig. 3C,D) . In contrast, in cells with downregulated MACC1 expression, the sensitivity of the cells to cisplatin was markedly increased (Fig. 3E,F) . Overall, the results showed that MACC1 could promote the development of Cis-Re in LC cells.
MACC1-mediated Cis-Re development in cancer cells
A549 and H446 cells were transfected with plasmids containing MACC1 or siRNA-MACC1 (shMACC1) coding sequences to further demonstrate the effect of MACC1 on the development of CisRe in LC cells. Cisplatin was added to cells with either upregulated or downregulated MACC1. The results revealed that cells overexpressing exogenous MACC1 demonstrated strong Cis-Re
Role of PI3K/AKT activation in MACC1-mediated Cis-Re
The mechanism of MACC1-mediated Cis-Re was investigated, and results revealed that AKT phosphorylation was inhibited in A549 and H446 cells in the presence of cisplatin. However, MACC1 overexpression attenuated cisplatin-induced AKT dephosphorylation (Fig. 4A,B) . These results indicated a regulatory effect on Cis-Re in LC cells, i.e. MACC1 could mediate the development of Cis-Re through the PI3K/AKT signaling pathway. To further confirm the regulatory effect, an inhibitor of the PI3K/AKT signaling pathway (perifosine) was added to A549 and H446 cells overexpressing MACC1. In these cells, the PI3K/AKT signaling pathway was clearly suppressed, and the Cis-Re induced by MACC1 was reversed (Fig. 4C,D) . These results suggested the involvement of the PI3K/ AKT signaling pathway in the development of Cis-Re induced by MACC1 in LC cells.
Synergistic effect of cisplatin and perifosine on the growth of cancer cells with Cis-Re
Perifosine was added to parental and cisplatin-resistant LC cells. Treatment with both cisplatin and perifosine was found to have a synergistic effect on cell viability. This combined treatment was more effective than the single administration of either agent in inhibiting the viability and inducing the apoptosis of A549, H446, A549/CR, and H446/CR cells (Fig. 5A,B) . In addition, a robust synergistic effect was observed in cells with Cis-Re, which was greater than that observed in parental cells (Fig. 5A) . Therefore, cisplatin in combination with perifosine could reverse the development of CisRe. These results in (A-D) are expressed as the mean ± SD of three independent experiments. *P < 0.05; **P < 0.01.
Suppression of the growth of cancer cells in MACC1-overexpressing xenografts by a combination of cisplatin and perifosine
To further elucidate the effect of MACC1 on the development of Cis-Re, in vivo experiments were carried out using MACC1-overexpressing xenografts. Tumor volume measurement and western blot analysis results confirmed the overexpression of MACC1 (Fig. 6A) . To demonstrate the synergistic effect of cisplatin and perifosine on the tumors, in vivo experiments in which tumor xenografts received a single administration of cisplatin (3 mg/kg), perifosine (25 mg/kg), or a combination of these agents were carried out. Cisplatin combined with perifosine showed a more robust inhibitory effect on tumor growth in comparison with the single administration of either agent. The synergistic effect on cell growth inhibition was more evident in cells overexpressing MACC1 than in control cells (Fig. 6B) , indicating that MACC1 can serve as a prognostic indicator of the response to the combined administration of cisplatin and perifosine in LC. Similar changes in apoptosis were also identified in the tumors (Fig. 6C) . The xenograft experiments revealed that cisplatin combined with perifosine could suppress the in vivo growth of tumor cells and antagonize the Cis-Re induced by MACC1. Furthermore, these results support the hypothesis that the PI3K/ AKT signaling pathway is a potential therapeutic target for reducing Cis-Re in tumor cells overexpressing MACC1.
Discussion
As an antitumor drug with promising efficacy, cisplatin is applicable to the treatment of various solid tumors [19, 20] . NSCLC is the leading cause of the sharp increase in cancer morbidity and mortality in Europe and North America [21] . Based on statistics, cisplatin-based combination therapy is recognized as the most efficient method for the treatment of NSCLC [22] . However, cells subject to cisplatinbased combination therapy are more susceptible to Cis-Re, and the efficacy of this method can only be sustained for a short time, despite a higher response rate than that from the use of individual medications [23] . Currently, researchers have proposed a number of hypotheses to explain the mechanism of Cis-Re; nevertheless, various mechanisms of Cis-Re may exist simultaneously in a single patient, resulting in tumor heterogeneity [24] . Hence, therapeutic methods targeting individual mechanisms usually have a poor efficacy [25] . Therefore, key pathways in the different mechanisms of Cis-Re should be identified to develop effective methods for the treatment of cancers [26] . In the present study, we generated drug-resistant cell lines to investigate Cis-Re. Generally, resistance is developed by exposing cells to drugs in a concentration gradient. After 6 months of exposing the cisplatin-sensitive A549 and H446 cells to cisplatin in a concentration gradient, cisplatin-resistant A549/CR and H446/CR cells were successfully established. The results of cell growth and apoptosis assays demonstrated that the biological features of A549/CR and H446/CR cells were different from those of A549 and H446 cells; cells with Cis-Re were inferior in growth and proliferation.
The involvement of MACC1, a key oncogene in tumor progression, in various mechanisms usually leads to poor clinical outcomes [27] . The modulatory effects of miR-338-3p and other factors on MACC1 have been identified in cancers; however, few studies have focused on the upstream regulation of MACC1 [28, 29] . A previous study revealed that MACC1 might be responsible for the poor prognosis of LC and enhance the Warburg effect, which could augment the resistance of tumor cells to metabolic stress, thereby accelerating tumor progression [30] . This finding demonstrated the vital role of MACC1 in some signaling pathways involved in LC.
Based on the unexpected observation that MACC1 was markedly upregulated in cells with Cis-Re, we hypothesized that MACC1 might be involved in the development of Cis-Re [31] . In gastric cancer cells, MET, which is responsible for the expression of the HGF receptor, serves as a transcriptional target of MACC1. Thus, the HGF-c-MET signaling pathway is potentially involved in the regulation of MACC1 in the development of Cis-Re [32, 33] . Considering that MACC1-regulated tumor cell growth is activated by the HGF/ c-MET/PI3K/AKT signaling pathway, we believe that the PI3K/AKT pathway may be a key pathway in the development of Cis-Re induced by MACC1 [15, 34] . This study revealed the correlation of MACC1 with the PI3K/AKT signaling pathway and its crucial role in the development of Cis-Re in LC cells. Therefore, the coupled MACC1-PI3K/AKT signaling pathway may be essential for the development of Cis-Re in LC cells. The down-regulation of MACC1 further promoted cell apoptosis induced by cisplatin, which could be reversed with an increase in AKT. The coupled MACC1-PI3K/AKT signaling pathway could serve as a target for the treatment of LC.
We also treated cisplatin-resistant A549/CR and H446/CR cells with a PI3K inhibitor and subsequently found that AKT phosphorylation was reduced in these cells with an increase in cisplatin sensitivity. This result suggests that the development of Cis-Re in A549/CR and H446/CR cells is associated with the MACC1-activated PI3K/ AKT pathway. Therefore, the activation of the PI3K/AKT pathway by MACC1 might contribute to the development of Cis-Re in A549/ CR and H446/CR cells, and this mechanism may be correlated with the increased expression of MACC1. The PI3K/AKT signaling pathway has been reported to mediate the development of tumor cell resistance to molecular-targeting treatments and chemotherapy. The PI3K/AKT pathway was also found to be inactivated when MACC1 was downregulated. Although the regulatory effect of MACC1 on the c-MET/AKT signaling pathway has been reported in cancers, the role of MACC1 in the regulation of the AKT feedback loop has not The indicated cell lines were treated with 2 μg/ml cisplatin, 5 μM perifosine, or a combination of both agents for 24 h. Apoptosis was analyzed by Annexin V/PI staining followed by flow cytometry (left). Caspase 3/7 activity was determined by fluorogenic analysis (right). The results in (A) and (B) are expressed as the mean ± SD of three independent experiments. *P < 0.05.
been established. The results of this study revealed the potential existence of an underlying feedback loop between MACC1 and the PI3K/AKT pathway, which needs to be confirmed in future studies. Our results also demonstrated the critical regulatory effect of the coupled MACC1-PI3K/AKT signaling pathway on the development of Cis-Re in LC cells. The apoptosis analysis results showed that a decrease in cell apoptosis was typically accompanied by an increase in MACC1 expression. On the other hand, the inhibitory effect of MACC1 could be offset by the presence of perifosine. Furthermore, cisplatin-induced cell apoptosis facilitated by MACC1 downregulation could be neutralized by addition of AKT. Therefore, the coupled MACC1-PI3K/AKT signaling pathway is critical for sustaining the survival of LC cells in the presence of cisplatin.
In conclusion, this study revealed the unique effect of MACC1 on Cis-Re in LC cells, which might be mediated by the activation the PI3K/AKT pathway. The findings of this study also demonstrated that treatment by targeting the PI3K/AKT pathway may lead to improvements in the clinical results of patients undergoing treatment for cancers, suggesting that combination therapy could counteract Cis-Re in LC cells overexpressing MACC1.
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